JTO创刊20周年:胸部肿瘤病理学进展回顾
本文回顾《Journal of Thoracic Oncology》创刊20年来发表的胸部肿瘤病理学重大进展,涵盖肺癌、间皮瘤、胸腺肿瘤和心脏肿瘤。病理学家主导的文章占该刊过去20年被引前20篇中的8篇,多项突破直接影响患者分层与治疗决策。
要点
- 病理学家主导文章占JTO过去20年被引前20篇的8篇。
- 病理进展主要集中在肺癌、间皮瘤、胸腺肿瘤和心脏肿瘤。
- 突破涉及外科病理、小活检与细胞学、新辅助治疗后管理、分子遗传与生物标志物检测。
核心结论
- JTO过去20年发表的病理学进展深刻影响了胸部肿瘤患者的分层与治疗管理决策。
研究设计与样本
- 本文为JTO创刊20周年系列综述,回顾该刊发表的胸部肿瘤病理学相关文章。
主要发现
- JTO过去20年被引次数前20的文章中有8篇由病理学家主导。
- 综述的病理进展主要涉及肺癌、间皮瘤、胸腺肿瘤和心脏肿瘤。
- 外科病理、小活检与细胞学、新辅助治疗后肺癌管理、分子遗传学和生物标志物检测等领域出现多项突破。
临床怎么用
- 病理学进展为胸部肿瘤患者提供了新的治疗管理决策分层方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In its 20-year history, the Journal of Thoracic Oncology (JTO) has published many major articles that have had a profound impact on the pathology of thoracic malignancies. One reason JTO has had such a great influence on thoracic oncology is the visionary leadership of the International Association for the Study of Lung Cancer (IASLC), which emphasizes an international, multidisciplinary approach across all its endeavors. JTO is one of the most important initiatives of the IASLC, and its global scope, encompassing all specialties, has enabled many pathologists to play a important role in the journal. This is reflected in the participation of multiple pathologists on the editorial board and in the prioritization of publishing impactful articles led by pathologists. This has been a good investment for JTO and IASLC, because eight of the top 20 most cited articles in the journal in the past 20 years were led by pathologists. This article reviews the many advances published in JTO, most of which concern lung cancer, mesothelioma, thymic tumors, and cardiac tumors. During this period, many breakthroughs occurred in surgical pathology, small biopsy and cytology, management of lung cancer after neoadjuvant therapy, molecular genetics, and biomarker testing. Many of these advances have had a direct impact on patient care, providing new ways to stratify patients for therapeutic management decisions.
引用
- Travis WD, Baine MK, Beasley MB, et al. Advances in Pathology: Journal of Thoracic Oncology 20th Anniversary Series. J Thorac Oncol. 2026. PMID: 42827012. doi:10.1016/j.jtho.2026.104116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。